B3 · BRL
BLAU3
Blau Farmaceutica SA
- Day's range
- R$10.39 – R$10.73
- Day's volume
- R$3.1m
- 52-week range
- R$8.28 – R$11.84
Follow BLAU3 on Fuolio
See how BLAU3 weighs in your net worth, what it has paid you and how far it is from your target allocation.
Create a free accountBLAU3 in numbers
- Market cap
- R$2.5bn
- P/E
- 10.68
- P/B
- 1.07
- Dividend yield (12m)
- 8.43%
- Net debt/EBITDA
- 1.00
The 12-month dividend yield of BLAU3 is 8.43%, above its 5-year average of 3.35%.
BLAU3 price history
BLAU3 risk and return
Monthly closes adjusted for splits and distributions.
| Metric | 12 months | 36 months | 60 months |
|---|---|---|---|
| Return | +12.14% | +4.70% | -55.60% |
| Volatility (annualised) | 33.07% | 36.84% | 36.40% |
| Largest drawdown | -23.92% | -37.92% | -71.58% |
| Positive months | 6/12 | 19/36 | 29/60 |
How much did investing in BLAU3 return?
R$1,000.00 invested on 01/10/2021 would be worth R$444.00 today.
- Value today in BLAU3
- R$444.00
- Return over the period
- -55.60%
- Return per year
- -15.00%
- In the Ibovespa
- R$1,777.43
With dividends reinvested, before taxes and costs, at month-end closes. Past returns do not guarantee future ones.
BLAU3 fundamentals
Valuation
- P/E10.68
- P/B1.07
- EV/EBITDA7.51
- EV/EBIT9.33
- EV/Revenue1.61
- P/EBIT8.09
- P/S1.40
- P/OCF5.89
- P/FCF-12.52
- Earnings yield10.72%
- PEG ratio—
- Earnings per shareR$1.00
- Book value per shareR$10.01
Debt
- Net debtR$383.2m
- Net debt/EBITDA1.00
- Net debt/Equity0.17
- Debt/Equity0.55
- Current ratio3.23
- Quick ratio2.25
- Cash ratio1.33
Efficiency
- Gross margin41.34%
- EBITDA margin21.48%
- Operating margin17.28%
- Net margin13.14%
- Asset turnover0.44
Profitability
- ROE10.02%
- ROA5.83%
- ROIC8.94%
- Payout90.03%
Growth
- Revenue CAGR (5 years)5.95%
- Earnings CAGR (5 years)-6.93%
- Revenue growth (year)-2.96%
- Earnings growth (year)35.80%
- Revenue growth (quarter)1.06%
- Earnings growth (quarter)-17.28%
What is BLAU3's fair price?
Two classic value formulas, with today's numbers. The current price is R$10.71.
- Graham's fair price
- R$15.03
- 40.30% above the price
√(22.50 × R$1.00 × R$10.01)
Benjamin Graham paid no more than a P/E of 15 and a P/B of 1.5. Their product, 22.5, times earnings (EPS) and book value per share gives the fair price.
- Bazin's ceiling price
- R$8.23
- 23.16% below the price
R$0.49 (5-year average) ÷ 6%
Décio Bazin only bought shares yielding at least 6% a year in distributions. The ceiling price is the average dividend per share of recent years divided by 6%.
Graham ignores growth and debt; Bazin assumes past distributions will repeat. They are reference points for comparison, not a buy recommendation.
BLAU3 indicators by year
Multiples at each year's closing price; margins and returns from that year's accounts.
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| P/E | 11.11 | 10.86 | 11.78 | 12.99 | 20.08 | — | — | — |
| P/B | 1.45 | 1.10 | 1.48 | 2.60 | 3.99 | — | — | — |
| EV/EBITDA | 8.80 | 7.73 | 10.08 | 9.84 | 13.20 | — | — | — |
| Dividend yield | 4.27% | 3.60% | 3.35% | 4.20% | 1.32% | — | — | — |
| Earnings per share | R$1.26 | R$1.21 | R$1.39 | R$2.03 | R$1.81 | R$1.72 | R$1.35 | R$0.83 |
| Book value per share | R$9.67 | R$11.99 | R$11.12 | R$10.13 | R$9.11 | R$1.50 | R$1.80 | R$1.51 |
| ROE | 13.08% | 10.10% | 12.52% | 19.99% | 19.89% | 114.90% | 75.35% | 55.19% |
| ROIC | 10.00% | 8.80% | 8.82% | 19.70% | 21.76% | 20.42% | 33.98% | 27.18% |
| Gross margin | 40.10% | 37.55% | 35.72% | 47.47% | 48.74% | 47.04% | 44.00% | 43.25% |
| EBITDA margin | 24.89% | 21.69% | 26.83% | 33.72% | 34.95% | 34.26% | 31.87% | 27.21% |
| Net margin | 17.33% | 12.38% | 18.20% | 25.83% | 23.80% | 21.52% | 20.48% | 15.76% |
| Net debt/EBITDA | 1.07 | 1.53 | 2.09 | -0.11 | -0.47 | 2.84 | 1.14 | 1.37 |
BLAU3 financial statements
| Line | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net revenue | R$1.7bn | R$1.8bn | R$1.4bn | R$1.4bn | R$1.4bn | R$1.2bn |
| Cost of sales | -R$1bn | -R$1.1bn | -R$882.4m | -R$739m | -R$700.5m | -R$625.8m |
| Gross profit | R$682.7m | R$658.8m | R$490.3m | R$667.9m | R$665.9m | R$556m |
| EBITDA | R$423.8m | R$380.6m | R$368.3m | R$474.5m | R$477.5m | R$404.9m |
| EBIT | R$354.4m | R$328.8m | R$329.4m | R$452.2m | R$456.6m | R$389.1m |
| Net finance result | R$34.1m | -R$36.9m | R$4.8m | R$16.4m | R$25.8m | -R$35.5m |
| Profit before tax | R$388.5m | R$291.9m | R$334.2m | R$468.6m | R$482.5m | R$353.6m |
| Income tax | -R$91.7m | -R$78.4m | -R$86.7m | -R$108.1m | -R$158.6m | -R$99.3m |
| Net income | R$295m | R$217.2m | R$249.8m | R$363.4m | R$325.2m | R$254.3m |
Figures the company filed with the CVM. Debt excludes leases; each quarter is that quarter alone.
BLAU3 against its sector
The same indicators for the company's other shares and the sector's largest stocks.
| Stock | P/E | P/B | Dividend yield (12m) | ROE | Market cap |
|---|---|---|---|---|---|
| BLAU3Blau Farmacêutica | 10.68 | 1.07 | 8.43% | 10.02% | R$2.5bn |
| HYPE3HYPERA S.A. | 9.87 | 1.19 | 4.42% | 12.10% | R$17.2bn |
| OFSA3OUROFINO S.A. | 5.88 | 1.68 | 5.01% | 28.55% | R$1.4bn |
| BIOM3BIOMM S.A. | 26.85 | 2.50 | 0.00% | 9.33% | R$814.3m |
| BALM3BAUMER S.A. | 9.76 | 1.28 | 21.91% | 13.16% | R$178.7m |
| BALM4BAUMER S.A. | 6.42 | 0.84 | 33.31% | 13.16% | R$178.7m |
Does BLAU3 pay dividends?
| Type | Last day to own | Payment | Per share |
|---|---|---|---|
| Interest on equity | 29/09/2026 | 08/10/2026 | R$0.08 |
| Dividend | 18/12/2025 | 31/12/2028 | R$0.56 |
Dividend yield per year
- 1.32%2021
- 4.20%2022
- 3.35%2023
- 3.60%2024
- 4.27%2025
- 1.41%2026
| Type | Last day to own | Payment | Per share |
|---|---|---|---|
| Interest on equity | 25/06/2026 | 07/07/2026 | R$0.08 |
| Interest on equity | 23/03/2026 | 02/04/2026 | R$0.08 |
| Interest on equity | 04/12/2025 | 16/12/2025 | R$0.11 |
| Interest on equity | 23/09/2025 | 03/10/2025 | R$0.10 |
| Interest on equity | 21/03/2025 | 02/07/2025 | R$0.15 |
| Interest on equity | 21/03/2025 | 01/04/2025 | R$0.11 |
| Interest on equity | 26/09/2024 | 20/12/2024 | R$0.08 |
| Dividend | 29/04/2024 | 25/10/2024 | R$0.01 |
| Interest on equity | 26/06/2024 | 10/07/2024 | R$0.14 |
| Interest on equity | 22/03/2024 | 10/04/2024 | R$0.13 |
| Dividend | 19/04/2023 | 22/12/2023 | R$0.05 |
| Interest on equity | 27/06/2023 | 30/10/2023 | R$0.12 |
See all 24 distributions
| Type | Last day to own | Payment | Per share |
|---|---|---|---|
| Interest on equity | 27/06/2023 | 14/07/2023 | R$0.07 |
| Interest on equity | 24/03/2023 | 17/04/2023 | R$0.18 |
| Interest on equity | 21/12/2022 | 29/12/2022 | R$0.18 |
| Interest on equity | 26/09/2022 | 17/10/2022 | R$0.17 |
| Interest on equity | 07/07/2022 | 15/07/2022 | R$0.16 |
| Interest on equity | 07/04/2022 | 19/04/2022 | R$0.14 |
| Dividend | 24/03/2022 | 05/04/2022 | R$0.21 |
| Dividend | 03/12/2021 | 15/12/2021 | R$0.12 |
| Interest on equity | 03/12/2021 | 15/12/2021 | R$0.12 |
| Interest on equity | 23/09/2021 | 05/10/2021 | R$0.11 |
| Interest on equity | 05/07/2021 | 15/07/2021 | R$0.02 |
| Interest on equity | 31/03/2021 | — | R$0.02 |
| Event | Last day to own | Ratio |
|---|---|---|
| Bonus shares | 05/01/2026 | 30.00% in shares |
About Blau Farmacêutica
- Sector
- Consumo Não Cíclico
- Segment
- Medicamentos e Outros Produtos
- Listing segment
- Novo Mercado
- Tag along
- 100.00%
- Free float
- 16.55%
- Shares issued
- 233.21m ordinary
- Average daily trading
- R$2.4m
- Listed since
- 19/04/2021
- CNPJ
- 58.430.828/0001-60
A Blau Farmacêutica S.A. é uma indústria farmacêutica brasileira com foco no mercado institucional hospitalar, atuando em medicamentos de alta complexidade nas linhas de biotecnológicos, oncológicos e especialidades. A companhia mantém plantas industriais e estrutura de pesquisa para desenvolvimento e produção de medicamentos injetáveis e biossimilares, além de operação comercial no Brasil e em países da América Latina. Listada na B3 sob BLAU3, a empresa combina fabricação própria, parcerias de desenvolvimento e estratégia de verticalização de insumos farmacêuticos. A geração de resultados depende de aprovação regulatória, capacidade produtiva, penetração em hospitais e dinâmica competitiva em produtos de maior valor agregado. No segmento institucional, contratos, previsibilidade de demanda e eficiência operacional são fatores centrais para margens e crescimento sustentável do negócio farmacêutico.
Investor website| Shareholder | Ordinary | Preferred | Total |
|---|---|---|---|
| MARCELO RODOLFO HAHNControlling | 82.50% | 0.00% | 82.50% |
| Outros | 16.55% | 0.00% | 16.55% |
| Ações Tesouraria | 0.96% | 0.00% | 0.96% |
Questions about BLAU3
How much is BLAU3 today?
BLAU3 is at R$10.71 (1.90% on the day), last traded on 30/09/2026.
How much did BLAU3 pay in dividends in 2025?
BLAU3 paid R$0.46 per share in 2025, a dividend yield of 4.27%.
When is the next BLAU3 dividend?
The next announced payment is R$0.08 per share on 08/10/2026.
What are the P/E and P/B of BLAU3?
BLAU3 trades at a P/E of 10.68 and a P/B of 1.07.
How much did BLAU3 return in 12 months?
BLAU3 returned 12.14% in 12 months, with annualised volatility of 33.07% and a largest drawdown of -23.92%.
What sector is BLAU3 in?
Blau Farmacêutica is in the Consumo Não Cíclico sector, Medicamentos e Outros Produtos segment.